Introduction
Type 1 diabetes mellitus (T1DM) requires lifelong treatment with insulin, and in the majority of cases results from a cell -mediated autoimmune destruction of the β -cells in susceptible individuals. This occurs after a long but variable preclinical period when islet autoantibodies to insulin, glutamine acid decarboxylase (GAD) and insulinoma -associated antigen 2 (IA -2) and other autoantigens can be detected [1] . Autoantibodies are not thought to cause the disease, but are markers of ongoing β -cell destruction. In general, the distinction between autoimmune T1DM (type 1 A according to the WHO [2] ) and non -autoimmune T1DM (type 1 B) is not necessarily useful for clinicians or epidemiologists. Problems with measurement error of autoantibodies, the likely existence of additional autoantibodies (as indicated by the recent discovery of zinc transporter 8 autoantibodies [3] ) and, perhaps equally important, the transient nature of autoantibodies, make accurate estimates of the proportion of autoimmune T1DM problematic. From longitudinal studies such as DAISY, it is known that some patients with newly diagnosed T1DM are negative for all autoantibodies at diagnosis while having previously been positive.
Genetic factors infl uence the susceptibility to T1DM, particularly human leukocyte antigen (HLA) genes [4, 5] . It is particularly the combination of HLA DR3 -DQ2 and DR4 -DQ8 that confers very high risk of T1DM, while those who carry only one
Keypoints
• Type 1 diabetes mellitus (T1DM) develops in genetically susceptible individuals after a preclinical phase of variable length usually with immune -mediated destruction of pancreatic β -cells, and requires lifelong treatment with insulin.
• The disease can occur at any age, but the incidence peaks around puberty. Classifi cation of T1DM vs type 2 diabetes (T2DM) becomes increasingly diffi cult with age. • In childhood, the incidence is similar in females and males, but there is a 1.3 -to 2.0 -fold male excess in incidence after about 15 years of age in most populations.
• The incidence in childhood varies enormously between countries. Some Asian and South American populations have low incidences (approximately 0.1 -8 per 100 000/year), while Finland ( > 40 per 100 000/year), Sardinia (approximately 38 per 100 000/year) and Sweden (approximately 30 per 100 000/year) have high incidences. North America (15 -25 per 100 000/year) and Australia (approximately 15 per 100 000/ year) have moderate to high incidences, while eastern countries in Europe have low to moderate incidences (4 -10 per 100 000/year).
• About 10 -20% of newly diagnosed childhood cases of T1DM have an affected fi rst -degree relative. Those with an affected sibling or parent have a cumulative risk of 3 -7% up to about 20 years of age, compared to cumulative risks of 0.2 -0.8% in the respective general populations. The cumulative incidence among the monozygotic co -twins of persons with T1DM is less than 50%, even after > 30 years ' follow -up.
• Some of the geographic differences and familial aggregation may be explained by human leukocyte antigen haplotypes.
• The incidence of childhood -onset T1DM has increased 3 -4% per calendar year, and there is a tendency towards younger average age at onset over time which cannot be explained by genetic factors. The causes of this increasing trend are not known.
• Virus infections and nutritional factors have been implicated, but no specifi c environmental factor has been established as a risk factor.
• Even though insulin replacement therapy and other advances in the management of T1DM have improved the prognosis of patients with T1DM, their mortality is still at least two times (approximately 2 -to 10 -fold) higher than in the background population. This is because of both acute and chronic complications of the disease, including cardiovascular disease after about 30 years of age.
Most of the incidence data available today come from studies of children in European countries. Incidence data from Africa are still sparse, but increased information on the incidence of T1DM among Asian and South American populations has changed the understanding of the global patterns in variation in incidence.
Occurrence of T 1 DM by a ge
In principle, T1DM may occur at any age, but it is very rare in the fi rst year of life and becomes increasingly diffi cult to distinguish from other types of diabetes after about 30 years of age. Essentially all populations display a steady increase in incidence rate with age up to around 10 -15 years [6] , but recent data from Finland indicate an incidence in 0 -to 4 -year -olds that is nearly as high as that in 10 -to 14 -year -olds [10] . The incidence rate increases from birth to peak at around puberty (Figure 3 .1 ) and in most populations is lower among 15 -to 29 -year -olds than among 0 -to 14 -year -olds [11 -15] . In some populations there seems to be a second rise in incidence after the age of about 25 -30 years [16 -18] .
In the Swedish nationwide prospective incidence study of 15 -to 34 -year -olds, 78% of the newly diagnosed patients were classifi ed as having T1DM and 15% as having type 2 diabetes mellitus (T2DM) at the time of the diagnosis [19] . The follow -up showed that 92% of patients diagnosed before 30 years of age were treated with insulin at a later date [20] . These fi ndings are consistent with recent incidence data from Finland among 15 -to 39 -year -olds [21, 22] . In these studies, the incidence of T2DM exceeded that of T1DM by the age of about 30 years. By contrast, in Turin, Italy, which has a much lower incidence of T1DM, the incidence of T2DM is about three times higher than that of T1DM at the age of 30 years [16] . Although beyond the scope of this chapter, it is important to consider the possible clinical heterogeneity and increasing diffi culty of classifi cation of diabetes with increasing of the two risk haplotypes have moderately increased risk. More details on the role of genetic factors and the pathologic process are covered in the fi rst part of Chapter 9 . Diagnosis of T1DM among children is considered relatively simple, typically with very high glucose levels and clear dependence upon insulin, but classifi cation and early detection becomes increasingly diffi cult with increasing age.
Occurrence of T 1 DM by a ge, s ex, p lace and t ime
The World Health Organization (WHO) DIAMOND Study (Multinational Project for Childhood Diabetes) [6] and the EURODIAB ACE Study [7, 8] have collected standardized incidence data for T1DM among children aged under 15 years, based on notifi cation by the diagnosing physician and date of diagnosis, defi ned as the date of fi rst insulin injection. In both projects, the degree of undercounting of cases has been estimated using a second source of information [9] .
Incidence rates are calculated as the number of new cases per 100 000 person -years, where person -years are estimated as the number of individuals in the population contributing the incident patients during the study period (mean population size in each calendar year, sex and age group) multiplied by the number of years covered by the age group in question. The proportion of the population expected to develop the disease by a certain age can be approximated by multiplying the average incidence rate in an age group by the number of years covered by the age group, the cumula tive incidence rate. For instance, if the average incidence rate among 0 -to 14 -year -olds is 20 per 100 000 personyears, then ([20/100 000] × 15 = 0.003 =) 0.3% of children in that popu lation will develop disease before they reach 15 years of age. The prevalence of disease among 0 -to 14 -year -olds is thus less than the cumulative incidence up to 15 years of age. Denmark, 1970 Denmark, -1976 .
While Sweden and Sardinia have higher incidence rates among children, the incidence rate among young adults was not much higher in Sardinia and Sweden than the other centers in the multicenter study [15] . Older data from Norway (1978 -1982) [13] indicated a higher incidence rate of 17 per 100 000/year and recent data from Finland (1992 -2001) [21] indicated an incidence rate of 18 per 100 000/year among 15 -to 29 -year -olds. Differences between countries in the incidence among young adults should be interpreted with caution until more data are collected using comparable methodology.
The USA is represented with the data collected during the 1990s from Allegheny County in Pennsylvania, Chicago and Jefferson County in Alabama, with incidence rates in the range 11 -18 per 100 000/year among children. Alberta and Calgary in Canada had slightly higher rates (about 23 per 100 000/year; Figure 3 .2 ) [6] , while the data from the Avalon Peninsula, Newfoundland, indicated a higher incidence rate of 35.9 per 100 000/year [32] .
In South America, children in centers in Venezuela, Paraguay and Colombia had incidence rates of less than 1 per 100 000/year, Chile (Santiago) had around 4 per 100 000/year, while Argentina and Brazil had an average of around 8 per 100 000/year. Many centers in Central America and the West Indies (except Puerto Rico and St. Thomas) generally have low to intermediate incidence rates, with indications of decreasing time trends [6] .
Data from New Zealand and parts of Australia show moderate to high incidence rates (15 -25 per 100 000/year) among children [6] . Data from other Pacifi c Island countries are lacking, and would be diffi cult to interpret because the populations in most island countries are small. In Asia, the mean incidence rate among the 23 centers in China during the early 1990s was 0.8 per 100 000/years. Japan has a slightly higher average incidence rate of 1.7 per 100 000/year among three centers, while Kuwait stands out with a high incidence rate of 22 per 100 000/year.
There is limited information on the incidence rate of T1DM from sub -Saharan Africa [33] . The fi ve DIAMOND centers are all in North Africa (Algeria, Libya, Sudan and Tunisia) or Mauritius, an island off the coast of Madagascar. Incidence rates reported from these centers range from low to intermediate, but these countries cannot be said to be representative of Africa. age [23, 24] . A proportion of the apparent heterogeneity may represent extremes within a continuum, although there is a need for more data in this fi eld [24] .
There is a lack of population -based incidence data for age groups above 35 years of age. The only published populationbased incidence studies covering the incidence of T1DM over the whole age span is one from Rochester, Minnesota, 1945 -1969 [25] and from Denmark, 1973 Denmark, -1977 . The latter study indicated that the cumulative probability of developing T1DM before age 80 years is in the range of 1 -1.5%.
Incidence by s ex
The peak in incidence rate among children occurs slightly earlier in girls than boys (Figure 3 .1 ), suggesting an infl uence of puberty. During the 1970s there was a male excess of T1DM in children in populations of European origin and a female excess in populations of African and Asian origin [27] ; however, during the early 1990s, the sex -specifi c pattern in incidence among children changed towards more modest differences. Of 112 centers with data during 1990 -1999, only six showed a signifi cantly excess of females (Beijing, Hong Kong and Zunyi in China, New South Wales in Australia, Puerto Rico and the Afro -American ethnic group in the USA) and six centers showed a signifi cant male excess (West Bulgaria, Finland, Attica in Greece, Switzerland, Oxford in the UK and the Dominican Republic), and all differences were generally of modest magnitude [6] . The general impression is still that it is the high incidence countries that tend to have a slight male excess, while the opposite is seen in low incidence countries. Many studies have shown a male excess in the incidence of T1DM among young adults [15, 28] . While the male : female ratio among children in most populations is 0.9 -1.1 [6] , the male : female ratio among young adults ranges from about 1.3 up to 2.0 in many populations [15, 28] .
Incidence by c ountry
The incidence rate of T1DM among childhood populations shows a vast geographic variation worldwide ( Figure 3 .2 ) [6 -8,29] . Over the period 1990 -1999, the age -adjusted incidence rate of T1DM ranged globally from 0.1 in Zunyi (China) and Caracas (Venezuela) to 37.8 in Sardinia and 40.9 per 100 000/year in Finland [6] . The most recent data from Finland indicate an incidence rate of nearly 60 per 100 000 in 2006 [10] , the highest incidence ever recorded.
European countries are well represented with registries, and there is an approximately 10 -fold difference between highest and lowest incidence countries in Europe [7] , with the apparently lowest rate of 3.6 per 100 000/year in Macedonia during 1989 -1994. Sweden has a high incidence rate (30 per 100 000/years). Centers from France and mainland Italy, for instance, report intermediate incidence rates around 10 per 100 000/year, while some other European countries have intermediate to high incidence rates [6] . In general, the incidence rates are low in eastern European countries, although the most recent EURODIAB data show that for several countries where the incidence rate previ-in the north and the east. In addition, there was a sixfold difference between the Mongol (1.82 per 100 000) and the Zhuang (0.32 per 100 000/year) ethnic groups [38] .
The variation in incidence within some countries may in part be because of ethnic heterogeneity of populations. For instance, the 1.5 -fold higher incidence among children in the South Island of New Zealand compared with that in the North Island was largely explained by the 4.5 times higher incidence among children of European origin compared to that among Maoris [39] .
Several methodological problems arise when making inferences based on epidemiologic studies of different ethnic groups and immigrants. These include differential ascertainment and
Variation in i ncidence w ithin c ountries, i ncluding by e thnic g roup
In several countries, marked within -country variations in the incidence rate of T1DM have been reported. For instance, up to 1.5 -fold differences have been described within relatively homogenous populations, such as Finland, Sweden and Norway [34 -36] . In Italy, the incidence rate among children in Sardinia 1990 -1999 (38 per 100 000/year) was three to six times higher than the average in mainland Italy, where the incidence rates vary twofold from 6.3 in Campania to 12.2 per 100 000/year in Pavia in the same period [37] . In China, there was a 12 -fold geographic variation (0.13 -1.61 per 100 000), generally with higher incidence 
Seasonal v ariation in d iagnosis of T 1 DM
Several studies have reported a peak in the number of cases diagnosed in the autumn and winter, and a smaller proportion of the cases diagnosed in the spring or summer, consistent both in the northern and southern hemispheres [7, 12] . Although reasonably consistent, there is some variation in exact peak and nadir between countries, age groups, sexes and periods. Generally, the degree of seasonal variation is stronger among those diagnosed at age 10 -14 years than in younger children ( Figure 3. 3 ) [7] . Different methods have been used in the analysis of seasonal variations, and often with data covering relatively short periods of time and limited number of cases; the results are therefore not necessarily comparable. Interpretation of seasonal variation must be carried out in light of the long and variable preclinical period in T1DM, and it is speculated that viral or other periodic factors have a role in the timing of the precipitation or onset of the disease in susceptible individuals who would develop it sooner or later.
Trends in i ncidence o ver t ime
The methodology for population -based incidence registries was not standardized until the late 1980s, but a number of older data sources have been reviewed to assess possible time trends. There is a general impression that the incidence of T1DM increased strongly after the middle of the 20th century [48, 49] , although in Denmark, the incidence among 0 -to 29 -year -olds seemed stable from 1924 to the 1970s [11] . An analysis of incidence trends of defi nition of ethnic group, underestimation of the base population in some ethnic groups, genetic admixture and possible heterogeneity in clinical presentation [24, 40, 41] . Among childhood onset cases, however, it seems that the large majority, even in Japan [42] , have classic autoimmune T1DM. Historically, the incidence of T1DM has been higher in populations of European origin, particularly those living in Europe, than that among populations of non -European origin [40, 41] . Despite the previously reported lower incidence among African -American and Latino populations in the USA, the incidence among these groups in the USA seems currently not very different from children of European origin in the USA [6, 41] . The incidence rates of T1DM in most South American studies with standardized registries seems to be much lower than that among Latino people in the USA and lower than that among Spaniards living in Spain [40] . The incidence of T1DM among children of immigrant parents to Germany, Sweden and mainland Italy has been shown to correlate with the incidence in the country or region of origin of their parents, whether the incidence in the country of origin is higher or lower [43 -45] ; however, the incidence among immigrants from Pakistan to the UK (or their children) is similar to that among the native Britons [46, 47] , despite the very much lower incidence recorded in Karachi, Pakistan [6] .
In summary, although there are clear ethnic differences in incidence rate of T1DM and strong evidence for a role of genetic factors, some of the abovementioned studies also support a role for yet unidentifi ed environmental factors. but not in Asia and North America [6] . A smaller relative increase in incidence rate over time among older individuals than among younger ones has also been seen in European studies covering wider age ranges [14, 17, 18, 52, 53] . This latter observation is in line with a model where a certain pool of genetically susceptible individuals contract the disease at younger ages [14, 17, 54] . The few available data, however, are not entirely consistent with this idea. An increasing incidence rate has been seen also among older age groups in some populations [18, 22, 31] , but the lack of standardized incidence data covering the whole age range makes it diffi cult to draw fi rm conclusions. Note that despite the time trends indicated in Sweden with decreasing average age of onset, the peak incidence rate remained around the age of puberty [14] .
Familial c lustering and t win s tudies
Besides providing clues regarding the relative importance of genetic and non -genetic factors in the etiology of disease, data on risk of T1DM among people with affected relatives may also aid the clinician in counseling of family members of newly diagnosed patients. Around 80 -90% of newly diagnosed T1DM patients do not have any affected siblings or parents, but fi rst -degree relatives of a person with T1DM are at increased risk. By the age of 20 years, approximately 4 -6% of siblings of T1DM probands have been reported to develop T1DM in European origin populations [55 -57] , compared with around 0.2 -1.0% in the corresponding background populations. The offspring of affected fathers have more standardized registry data from 1960 to 1996 in 37 populations worldwide showed a signifi cant increase in incidence rate over time in the majority of populations, with a steeper relative increase in low -incidence than in high -incidence populations [50] . In Finland, the incidence rate has increased linearly from the mid 1960s to the mid 1990s [51] and thereafter even more steeply, reaching almost 60 per 100 000/year in 2006 ( Figure 3 .4 ) [10] .
In the 103 centers participating in the WHO DIAMOND project for at least 3 years during 1990 -1999, the overall relative increase in incidence rate was 2.8% per year [6] . By continent, overall increasing trends per year were estimated at 5.3% in North America, 3.2% in Europe and 4.0% in Asia [6] . The only region with an overall decreasing trend was Central America and the West Indies [6] .
In general, the increasing trend appeared to be strongest in the centers with high and very high incidence rates during the 1990s. In the centers with low and very low incidence rates, there were no signifi cant increases in incidence rates over time. However, the 15 -year (1989 -2003) time trends in Europe reported to EURODIAB indicated an overall mean increase in incidence rate of 3.9% per year, with a tendency towards stronger relative increases in the countries with lowest average incidence rates during the fi rst 5 years (1989 -1994) [8] .
Overall, the relative increase over time during the 1990s among the DIAMOND centers was most pronounced in the younger age group: 4.0% among 0 -to 4 -year -olds, 3.0% in the 5 -to 9 -year -olds and 2.1% in the 10 -to 14 -year -olds, similar for boys and girls in most centers. The pattern of a steeper relative increase among the youngest was seen in Europe and Oceania, 
Environmental r isk f actors for T 1 DM : c lues from e pidemiologic s tudies
The time trends described above must be ascribed to some change in the environment, even in the event that the increase is brought about by a change in the age distribution. Some of the variation in incidence rate between European countries can be explained by differences in the frequency of HLA susceptibility genotypes [66] , but clearly not all [67] . It has recently been suggested that the proportion of newly diagnosed patients with T1DM who carry the highest risk genotype (DR3 -DQ2/DR4 -DQ8) has decreased over time (reviewed in [68] ). It may be speculated that increased exposure to some risk factor or decreased exposure to some protective factor have caused more individuals with moderate risk ( " permissive " ) genotypes (e.g. either DR3 -DQ2 or DR4 -DQ8, but not both) to develop T1DM in recent years. Although there is overwhelming evidence for an essential role of genetic factors in the etiology of T1DM, available evidence strongly suggests that one or more non -genetic factors are also involved; however, the nature of these putative factors are not well known.
In general, environmental factors may be envisioned to have a role in the following: 1 Initiating of the autoimmune disease process; 2 Modulating the progression from islet autoimmunity to clinical T1DM; or 3 " Precipitating " disease in individuals with advanced preclinical disease. Little is known about the initiation of autoimmunity in humans [69] , but some form of immune -mediated mechanism leading to the breakdown of self -tolerance is likely to be involved. Limited geographic variation in the prevalence of islet autoim-1.5 -3 times increased risk of T1DM compared with the offspring of affected mothers [58, 59] . By 20 years of age, 5 -8% of the offspring of men with diabetes, but only 2 -5% of the offspring of women with diabetes have been found to be affected. There is currently no accepted explanation for this phenomenon.
Given the well -established effect of genetic factors, there is no surprise that the concordance rate for T1DM in monozygotic (MZ) twins is much higher than that in dizygotic (DZ) twins [60, 61] . In one study from North America, the estimated cumulative risk 10 years after onset in the proband (diagnosed before age 40 years) was about 25% in MZ twins and about 11% in DZ twins [62] . Corresponding 10 -year cumulative risks from Finland were estimated to 32% for MZ twins and 3.2% for DZ twins [61] . Comparable estimates were also found in the Danish twin registry, although the exact age at onset was not known in this study [60] . In general, the risk for the co -twins was higher and the discordance time shorter the earlier the onset in the proband [61 -63] . In a long -term follow -up of discordant MZ twins from the USA and the UK, more than 50% of MZ pairs remained discordant for T1DM (Figure 3 .5 ) [63] . Because MZ twins share 100% of their genomic DNA, this suggests that genetic susceptibility is in most cases not suffi cient for the development of disease.
Despite the relatively high proportion of MZ twins being discordant for clinical T1DM, many of the non -diabetic co -twins of patients with T1DM develop islet autoimmunity [64] . Together with the limited variation in prevalence of positivity for islet autoantibodies between countries [54] and animal studies suggesting a two -stage disease process [65] , this supports the idea that environmental factors may have a more important role in the progression from islet autoimmunity to overt disease. capsid protein VP1 in 44 of 72 cases. Very few of the controls in that study stained positive [77] . This study substantiated previous evidence based on one or a few patients [73, 74] and indicated problems with the methods used in a previous study of a similar material where no such evidence was found [84] . Nevertheless, to confi rm these fi ndings in the future, in situ hybridization should be used to assess the presence of enterovirus RNA (rather than protein) in a larger number of islets from people with recent onset T1DM and the lack thereof in appropriate controls. Enterovirus infections are common and there is evidence that the frequency of infection has decreased with improved hygiene in the recent decades, opposite to the trend seen for T1DM. It has been postulated that the increasing incidence of T1DM in children may in part be explained by decreased protection from maternal enterovirus antibodies [85] . A more direct test of this hypothesis is still lacking. The so -called " hygiene hypothesis " comes in different versions but essentially proposes that the decline in microbial exposure in many populations over the past few decades has caused the concomitant increase in incidence of immune -mediated diseases including T1DM [86] . Some infections and microbial agents reduce the incidence of autoimmune diabetes in experimental animals [74] . Epidemiologic studies have investigated non -specifi c infections and infectious symptoms, but the results have been inconsistent. Daycare attendance is usually associated with increased exposure to microbial agents, and a recent metaanalysis concluded that there is some evidence for a lower risk of T1DM among children who attended daycare centers early in life, but the results were not suffi ciently homogenous to allow a strong conclusion [87] .
There are many promising observations supporting a possible role of viral infections in the etiology of T1DM, but the current evidence that infections have an important and causal role in human T1DM is not conclusive. Although the problem of identifying the potential strain of enterovirus that might be diabetogenic would pose an additional problem, vaccine development towards such a strain might be envisioned in the future as a preventive measure, but it is currently unknown whether or when this could be feasible.
Toxins
The rodenticide Vacor has been associated with T1DM in humans after ingestion of large doses [88] . There are structural and mechanistic similarities between Vacor and streptozotocin and alloxan [88] , which are specifi cally toxic to β -cells, and used to induce diabetes in experimental animals [88, 89] . Some epidemiologic studies have assessed intake of nitrates and nitrites, which may be converted to related N -nitroso -compounds, but most studies have used ecologic study designs and assessed levels in community drinking water, which is probably a poor indicator of total exposure. A potential diabetogenic role of in utero exposure to bafi lomycin, a toxin produced by bacteria growing on the skin of root vegetables such as potatoes, has been suggested based on experiments with rodents and in vitro studies [90] . In a prospecmunity despite the large differences in incidence of T1DM between countries suggests a major importance of environmental factors in the progression from islet autoimmunity to T1DM [54] , although the hypothesis that there are environmental triggers of autoimmunity cannot be discarded [70] . Responsible factors may operate by modulating the immune system and metabolism. In vitro experiments have suggested that actively insulin -secreting β -cells hyperexpress islet autoantigens such as GAD, and are more susceptible to toxic effects of the cytokine interleukin 1 β ( 71 ). It may be speculated that factors that increase the stress on β -cells may non -specifi cally contribute to the precipitation of clinical disease [71] . This includes insulin resistance or other mechanisms implied in infections, puberty and growth spurts. Insulin resistance is not easy to measure reliably in humans, but several studies have found measures of insulin resistance relative to fi rst -phase insulin response to an intravenous glucose tolerance test to be predictive of progression to T1DM (reviewed in [72] ). Below, some of the most frequently studied non -genetic factors with a potential role in the etiology of human T1DM are discussed.
Specifi c p utative e nvironmental f actors

Viral i nfections
There is a large body of literature linking infections and T1DM, ranging from in vitro studies [73] , experiments with various animal models [74] , clinical and pathologic studies of patients with disease [73,75 -77] and epidemiologic case -control and cohort studies [12, 70, 78] . Congenital rubella syndrome (CRS) has been associated with a several -fold increase in the incidence of T1DM [79] . Although not contributing to the incidence of T1DM in most countries today, this observation has been cited as a proof of principle that intrauterine factors and viral infections in general can infl uence the risk of T1DM in humans. It probably remains the best example of a non -genetic factor contributing to increased risk of T1DM in humans, but the consistency of the available evidence and the absolute risk associated with CRS may have been overstated [80, 81] .
Several early studies based on assays for antibodies to enteroviruses in cases with T1DM and controls initially seemed promising, but systematic review of the data showed too much heterogeneity in methodology and results to draw any conclusion [78] . Prospective study design and detection of enterovirus RNA represent important contributions to the methodology of such studies in recent years. Increased risk of childhood onset T1DM has been associated with evidence of maternal enterovirus infections during pregnancy in some studies, but not in all [82] . Using both serum enterovirus antibodies and RNA as indications of postnatal infection, independent prospective studies from Finland have found enterovirus to be associated with increased risk of islet autoimmunity and T1DM [70] , while other similar studies have not found any signifi cant association [83] . A recent immunohistochemical study of stored sections of pancreatic biopsies obtained postmortem in young individuals with recent onset T1DM found that the β -cells of multiple islets stained positive for enterovirus fatty acids rather than vitamin D. Although recall bias cannot entirely be ruled out from the latter study, support for the hypothesis that intake of dietary n -3 fatty acids may prevent islet autoimmunity and/or T1DM recently came from a prospective study including both dietary assessment and analysis of fatty acid composition of red cell membranes, which is a biomarker of n -3 fatty acid status [104] . Plans are underway to initiate a randomized intervention trial to prevent islet autoimmunity and/or T1DM using DHA supplements.
Despite previous indications from two prospective studies that serum alfa -tocopherol (vitamin E) could be associated with lower risk of T1DM, there was no association with advanced islet autoimmunity or T1DM in early life in the DIPP study [105] . In conclusion, the role of nutritional factors in T1DM remains uncertain.
Perinatal f actors and p ostnatal g rowth
Offspring of non -diabetic mothers aged 35 years or more when giving birth have an approximately 20 -30% increased risk compared with offspring of mothers who are 25 years or less [106 -108] . Results for birth order and for paternal age have been less consistent [106, 108] . Birth by cesarean section was recently associated with an approximately 20% increased risk of T1DM in children according to meta -analysis of 20 published studies [109] . Although there is some potential for selection bias in the casecontrol studies included, and the mechanism is unknown, it was speculated that delayed colonization of the infant ' s intestine associated with cesarean section may be involved.
Increased birth weight has been associated with a relatively weak but signifi cant increase in risk of childhood onset T1DM in large cohort studies based on linkage of population registries, independent of maternal diabetes and other potential confounders [108,110 -112] . There are also studies reporting no signifi cant association, but these were generally smaller casecontrol studies. The association seems in most cases to be independent of gestational age. Indirect data suggest that the association with birth weight may in part be explained by HLA genes [113] , but a study directly testing this idea found that this was not the case [114] . Birth weight is certainly only a marker of some other phenomenon and the mechanisms involved remain to be defi ned.
Associated factors such as postnatal growth or excess body weight might be of relevance. A number of studies have indicated that children developing T1DM are taller, heavier or gain more weight or height prior to diagnosis compared to their peers [95,115 -121] . Because of the numerous size and growth variables included and the various methods of analysis used in these studies, a systematic review of the consistency of these associations is warranted.
In summary, environmental factors may infl uence individuals quite differently, depending on the genetic background, although direct evidence for specifi c gene -environment interactions from humans is scarce [80] . No specifi c single factor has been identifi ed thus far. Taking into account the multifactorial nature tive study there was no support for the idea that frequent potato consumption during pregnancy could increase the risk of islet autoimmunity in the offspring, but it is unknown whether frequency of potato intake really is a marker for bafi lomycin exposure [91] . In conclusion, there is little direct evidence for a widespread role of toxins in human T1DM, but this may refl ect the lack of well -conducted studies.
Nutritional f actors
Several possible plausible mechanisms have been proposed to link dietary factors to T1DM, including " molecular mimicry " and a detrimental effect of bovine insulin in cow ' s milk (reviewed in [92] ). A reduced risk conferred by prolonged breastfeeding and/ or delayed introduction of cow ' s milk has been suggested in many case -control studies, but most of these studies were susceptible to recall bias and the issue is controversial [93] . In the largest prospective study to date involving multiple islet autoantibodies or T1DM as the endpoint, there was no signifi cant association with duration of exclusive or total breastfeeding [94] . Duration of breastfeeding was also not associated with self -reported T1DM up to age 30 years in a recent prospective study including 61 cases [95] . It is hoped that an ongoing randomized controlled trial (TRIGR) will provide an answer to whether delayed introduction of cow ' s milk protein can reduce the risk of islet autoimmunity and T1DM [96] . Two prospective studies of islet autoimmunity have provided some evidence for a role of age at introduction of cereals or gluten [97, 98] , although the relation is complex and diffi cult to interpret.
The immunomodulatory effects of vitamin D and preventive effect of pharmacologic (hypercalcemic) doses of 1,25 -dihydroxyvitamin D on diabetes development in experimental animals have been documented in several studies [99] . Systemic concentration of 1,25 -dihydroxyvitamin D is tightly controlled by hydroxylation of 25 -hydroxyvitamin D, and this must be taken into account when evaluating experimental results from animal models. Vitamin D is also produced in the skin upon exposure to ultraviolet light, and no prospective study has yet been published of serum 25 -hydroxyvitamin D, which is an established marker of vitamin D status, and risk of T1DM. A multicenter case -control study found a signifi cantly lower risk of T1DM associated with reported use of vitamin D supplement in early life [100] , although recall and selection bias may have affected these fi ndings; however, this was also supported by a prospective Finnish study [101] . Prospective studies of maternal intake of vitamin D via food during pregnancy and risk of islet autoimmunity in children have not produced convincing evidence for any relation [102] .
A case -control study in Norway found an association between use of cod liver oil in the fi rst year of life and lower risk of T1DM [103] . Cod liver oil, which is commonly used in Norway, is an important source of both vitamin D and long -chain n -3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) in this population. The lack of association with other vitamin D supplements in these studies supports a role of n -3 suggested for the prevention of long -term complications [132] . After about 10 -15 years of diabetes duration, microvascular and macrovascular chronic diabetes complications start to make an impact, and after about 30 years of age cardiovascular causes become increasingly important. The relative mortality from cardiovascular causes is at least as high for women as for men. SMRs for cardiovascular causes of death of 8 -40 have been reported in patients with T1DM, and it depends strongly on nephropathy (reviewed in [133] ).
There is growing evidence that better glycemic control and improved risk factor control such as lowering of blood pressure and lipids is associated with reduced risk of late complications and improved survival (reviewed in [122, 133] ). The trend in mortality among patients with long -term T1DM seems to be improving [122] , but there is a paucity of large cohorts with longterm follow -up of incident cases of T1DM covering long time periods to assess general trends after the late 1980s. Another challenge is the continued deaths of undiagnosed cases of T1DM and patients without access to care in the developing world.
Conclusions
T1DM is one of the most common chronic diseases diagnosed in childhood, but the disease can occur at any age. Its incidence varies drastically between populations and even within populations. T1DM has a strong genetic component and familial clustering, but the majority of cases have no affected siblings or parents. Only a minority of carriers of the susceptibility genes develop T1DM. The incidence of T1DM is increasing in most studied populations at an average rate of approximately 3 -4% per year. The causes of this increase are not known. It is believed that some environmental factors may have contributed to it, but no defi nite causal environmental factor for autoimmune T1DM has yet been identifi ed.
T1DM was a fatal disease before the insulin era. Although mortality in patients with diabetes has drastically decreased, both acute and late complications lead to increased morbidity and premature mortality in T1DM. Primary prevention of T1DM would be the only solution to these problems, but unfortunately no practical preventive measures are currently available. of T1DM, specifi c environmental risk factors with suffi ciently large impact to be of clinical importance and detectable in epidemiologic studies may not exist; however, identifi cation of potential environmental risk factors and their role in the disease process is important in the potential prevention of T1DM in the future, and lack of consistent fi ndings may refl ect lack of properly conducted prospective studies. There are several randomized controlled trials ongoing with various interventions that are aiming at reducing the risk of islet autoimmunity or progression from islet autoimmunity to T1DM (see the fi rst part of Chapter 9 ). Given the enormous amount of resources necessary for such efforts and the negative results of completed trials, it may be wise to initiate such trials based on consistent fi ndings from properly conducted prospective observational studies. The large multicenter longitudinal TEDDY study may contribute towards this goal ( http://www.niddk.nih.gov/patient/ teddy/teddy.htm ).
Mortality
Before the discovery of insulin in 1922, T1DM meant an almost certain death soon after its onset. After the initiation of insulin replacement therapy, a dramatic improvement in survival occurred [122] . Another major improvement in survival occurred in cases of diabetes diagnosed in the 1950s [123] ; however, even today T1DM is associated with an approximately 2 -to 10 -fold excess risk of premature mortality [121,124 -128] . A large variation in relative mortality has been reported from different countries. For instance, the standardized mortality ratio (SMR) for patients with T1DM in Finland was lower than that in Lithuania, Estonia and in Japan [129, 130] . A higher mortality in AfricanAmerican compared to white patients with T1DM in the USA has been reported, and this difference seems to be attributable to acute complications [131] .
Recent data from Europe showed that the short -term mortality was two times higher in patients followed from diagnosis of T1DM in childhood than the respective general populations, with variation in the SMR from about 1.1 to 4.7 in different countries [128] . In a nationwide cohort of patients with T1DM in Norway followed from onset before 15 years of age and up to 30 years ' duration (mean 24.2 years), the SMR was 4.0 [126] . In a UK cohort of more than 7000 prevalent cases of T1DM with mean age of 33 years at baseline, the SMR after up to 7 years of followup (mean 4.5 years) was 3.7 [125] . Many studies have reported that the SMR varies with age and with diabetes duration, or both, but results are not consistent among studies [122] .
Ascertainment of cause of death is diffi cult, but around onethird of the early deaths in the recent European multicenter study were clearly attributable to diabetic ketoacidosis (DKA), while about half of the relatively few deaths among young people with T1DM seems to be unrelated to diabetes [127, 128] . Hypoglycemia as a cause of death is currently rare compared to DKA, but potentially increasing because of the more vigorous glycemic control
